NCT05081167View on ClinicalTrials.gov

A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)

PHASE3CompletedINTERVENTIONAL
Enrollment

232

Participants

Timeline

Start Date

June 2, 2021

Primary Completion Date

September 13, 2022

Study Completion Date

September 14, 2022

Conditions
Major Depressive Disorder
Interventions
DRUG

REL-1017

REL-1017 tablet

DRUG

Placebo

Placebo tablet

Trial Locations (10)

32751

Relmada Site, Maitland

32801

Relmada Site, Orlando

32905

Relmada Site, Palm Bay

33015

Relmada Site, Miami

33166

Relmada Site, Miami Springs

33175

Relmada Site, Miami

60634

Relmada Site, Chicago

78737

Relmada Site, Austin

02116

Relmada Site, Boston

02472

Relmada Site, Watertown

All Listed Sponsors
lead

Relmada Therapeutics, Inc.

INDUSTRY